CSI Market
Sign In | Register

Kuvatris Therapeutics Inc (PXMD) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access PXMD Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Kuvatris Therapeutics Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2024)
9 Months 		(Jun 30 2024) (Mar 31 2024) (Dec 31 2023) (Sep 30 2023)
Operating Activities
Income-7.57
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation1.51
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Fair Value Adjustment Of Convertible Notes-
Fair Value Adjustment Of Simple Agreement For Equity Liability-
Adjustments For Gain Loss On Issuance Of Debt-
Adjustments For Gain Loss On Conversion Of Notes-
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable, Trade1.32
Increase (Decrease) in Accrued Liabilities-0.86
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other0.59
Other Working Capital0.00
Other Noncash Expense0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-5.00
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-3.97
Proceeds From Safe Investment-
Proceeds From Convertible Promissory Notes And Warrants-
Payments Of Costs Incurred In Connection With Convertible Promissory Notes-
Proceeds From Issuance Of Common Stock Equity Purchase Agreement-
Payments Of Costs Incurred In Connection With Equity Purchase Agreement-
Proceeds From Issuance Of Common Stock And Warrants-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents4.71
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.74
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-5.00
Total Cash Flow-4.27
4 historic quarters locked

Sign in to unlock the full Kuvatris Therapeutics Inc cash flow history.

Sign In Create Free Account

About Kuvatris Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20240930)
  • Filed with the SEC: January 14, 2026
  • Source: form10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001493152-26-002270

Figures are derived from filed reports and may be restated. Historical data is subject to revision.